Ferrante RJ - Search Results

1

Regional and progressive thinning of the cortical ribbon in Huntington's disease.

Rosas HD, Liu AK, Hersch S, Glessner M, Ferrante RJ, Salat DH, van der Kouwe A, Jenkins BG, Dale AM, Fischl B. Rosas HD, et al. Among authors: ferrante rj. Neurology. 2002 Mar 12;58(5):695-701. doi: 10.1212/wnl.58.5.695. Neurology. 2002. PMID: 11889230

2

Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG.

Hersch SM, Gevorkian S, Marder K, Moskowitz C, Feigin A, Cox M, Como P, Zimmerman C, Lin M, Zhang L, Ulug AM, Beal MF, Matson W, Bogdanov M, Ebbel E, Zaleta A, Kaneko Y, Jenkins B, Hevelone N, Zhang H, Yu H, Schoenfeld D, Ferrante R, Rosas HD. Hersch SM, et al. Neurology. 2006 Jan 24;66(2):250-2. doi: 10.1212/01.wnl.0000194318.74946.b6. Neurology. 2006. PMID: 16434666 Clinical Trial.

3

Huntington aggregates may not predict neuronal death in Huntington's disease.

Kuemmerle S, Gutekunst CA, Klein AM, Li XJ, Li SH, Beal MF, Hersch SM, Ferrante RJ. Kuemmerle S, et al. Among authors: ferrante rj. Ann Neurol. 1999 Dec;46(6):842-9. Ann Neurol. 1999. PMID: 10589536

4

Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease.

Ferrante RJ, Andreassen OA, Dedeoglu A, Ferrante KL, Jenkins BG, Hersch SM, Beal MF. Ferrante RJ, et al. Among authors: ferrante kl. J Neurosci. 2002 Mar 1;22(5):1592-9. doi: 10.1523/JNEUROSCI.22-05-01592.2002. J Neurosci. 2002. PMID: 11880489 Free PMC article.

5

Translating therapies for Huntington's disease from genetic animal models to clinical trials.

Hersch SM, Ferrante RJ. Hersch SM, et al. Among authors: ferrante rj. NeuroRx. 2004 Jul;1(3):298-306. doi: 10.1602/neurorx.1.3.298. NeuroRx. 2004. PMID: 15717031 Free PMC article. Review.

6

The therapeutic role of creatine in Huntington's disease.

Ryu H, Rosas HD, Hersch SM, Ferrante RJ. Ryu H, et al. Among authors: ferrante rj. Pharmacol Ther. 2005 Nov;108(2):193-207. doi: 10.1016/j.pharmthera.2005.04.008. Epub 2005 Aug 1. Pharmacol Ther. 2005. PMID: 16055197 Review.

7

Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice.

Stack EC, Kubilus JK, Smith K, Cormier K, Del Signore SJ, Guelin E, Ryu H, Hersch SM, Ferrante RJ. Stack EC, et al. Among authors: ferrante rj. J Comp Neurol. 2005 Oct 3;490(4):354-70. doi: 10.1002/cne.20680. J Comp Neurol. 2005. PMID: 16127709

8

Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease.

Matthews RT, Yang L, Jenkins BG, Ferrante RJ, Rosen BR, Kaddurah-Daouk R, Beal MF. Matthews RT, et al. Among authors: ferrante rj. J Neurosci. 1998 Jan 1;18(1):156-63. doi: 10.1523/JNEUROSCI.18-01-00156.1998. J Neurosci. 1998. PMID: 9412496 Free PMC article.

9

Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice.

Jenkins BG, Klivenyi P, Kustermann E, Andreassen OA, Ferrante RJ, Rosen BR, Beal MF. Jenkins BG, et al. Among authors: ferrante rj. J Neurochem. 2000 May;74(5):2108-19. doi: 10.1046/j.1471-4159.2000.0742108.x. J Neurochem. 2000. PMID: 10800956 Free article.

10

Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.

Ferrante RJ, Andreassen OA, Jenkins BG, Dedeoglu A, Kuemmerle S, Kubilus JK, Kaddurah-Daouk R, Hersch SM, Beal MF. Ferrante RJ, et al. J Neurosci. 2000 Jun 15;20(12):4389-97. doi: 10.1523/JNEUROSCI.20-12-04389.2000. J Neurosci. 2000. PMID: 10844007 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

171 results

Search Page